
All News
All series
All All News










Once weekly Kyprolis (carfilzomib) had better efficacy than lower-doses of the drug given twice a week to treat patients with relapsed/refractory multiple myeloma, according to results from the phase 3 ARROW trial.

Consistently living in the past with a cancer diagnosis will never let you just enjoy the life of the present.

Shared breathing can help support and promote the sensual experience for survivors of cancer.

Cancer survivor shares how cancer survivorship impacts her life choices as she moves forward.

Surviving cancer helped shine the light on my five most important possessions.

The annual mammogram can be triggering for survivors. They could use a little more TLC from the system during this annual ritual.

It isn't always so "normal," is it?

Older patients with acute myeloid leukemia (AML) often face a difficult choice: risky, intensive chemotherapy that offers a small chance of a cure versus non-intensive chemotherapy meant to improve physical comfort and quality of life.

Specifically, the study demonstrated that patients with advanced cancer prefer that their physicians speak with them while holding a note pad, rather than while typing into computers that link to electronic health records.

Patients and their caregivers saw physical and emotional improvements after starting yoga.

Targeted intervention is effective in improving psychosocial stress experienced by many adolescent and young adult (AYA) patients with cancer, according to a study released ahead of the 2017 Palliative and Supportive Care in Oncology Symposium to be held Oct. 27-28 in San Diego.

The combination of Tafinlar (dabrafenib) and Mekinist (trametinib) was granted a breakthrough therapy designation by the Food and Drug Administration (FDA) for the adjuvant treatment of patients who have stage 3 melanoma and a BRAF V600 mutation, after they have already had a complete resection.

The largest ruling yet was overturned by a California judge on Oct. 20.

The combination of the immunotherapies Opdivo (nivolumab) and Yervoy (ipilimumab) sparked a response in nearly half of asymptomatic patients with melanoma brain metastases who had not received prior local therapy to the brain.

The longest response rate lasted six months.

The fear of recurrence is real, but taking a lighthearted look at it sometimes helps lessen the fear.

A guy who knows breast cancer shares some surgical tips.

Although chemotherapy has been used to treat patients with Merkel cell carcinoma, immunotherapy agents show great promise, according to findings presented at the 2017 World Congress of Melanoma.

Cancer survivor notices difficulty with changes and transitions since cancer.

Prosthesis is another word added to my cancer vocabulary.

A cancer survivor describes her rocky road to learning a new art form to help her heal.





